Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy

A Southwest Oncology Group study

H. Barton Grossman, Catherine M. Tangen, Carlos Cordon-Cardo, Richard J Cote, Frederic M. Waldman, Ralph W. De Vere White, Anand B. Karnad, Michael Glode, E. David Crawford

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In this prospective biomarker study, we evaluated the prognostic significance of Ki67, p53 and angiogenesis in patients with locally advanced bladder cancer. The patients were volunteers from a Southwest Oncology Group trial of locally advanced bladder cancer who were randomized to treatment with neoadjuvant chemotherapy plus cystectomy or cystectomy alone. Tissue specimens were obtained prior to neoadjuvant chemotherapy from 42 patients randomized to receive the combination-treatment arm and 52 randomized to cystectomy alone. The statistical power of the study was quite limited by the small sample size. The biomarkers were assayed by immunohistochemistry. Angiogenesis was determined using anti-CD34 immunostaining. Patients whose tumors had increased Ki67 expression had better progression-free survival that was marginally significant, p=0.063. The median survival in those with higher Ki67 expression was 73 months, and in those with lower expression was 38 months. However, this did not achieve statistical significance, p=0.25. There was a suggestion of worse survival among patients whose tumors exhibited altered p53 staining [hazard ratio (HR) = 1.48; p=0.15], but there was no difference in progression-free survival (HR=1.02; p=0.93). The enumeration of tumor microvessels did not provide prognostic information.

Original languageEnglish
Pages (from-to)807-810
Number of pages4
JournalOncology Reports
Volume16
Issue number4
StatePublished - Oct 1 2006
Externally publishedYes

Fingerprint

Cystectomy
Drug Therapy
Urinary Bladder Neoplasms
Disease-Free Survival
Biomarkers
Neoplasms
Neoadjuvant Therapy
Survival
Microvessels
Sample Size
Volunteers
Immunohistochemistry
Prospective Studies
Staining and Labeling

Keywords

  • Angiogenesis
  • Bladder cancer
  • Ki67
  • p53

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Grossman, H. B., Tangen, C. M., Cordon-Cardo, C., Cote, R. J., Waldman, F. M., De Vere White, R. W., ... Crawford, E. D. (2006). Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group study. Oncology Reports, 16(4), 807-810.

Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy : A Southwest Oncology Group study. / Grossman, H. Barton; Tangen, Catherine M.; Cordon-Cardo, Carlos; Cote, Richard J; Waldman, Frederic M.; De Vere White, Ralph W.; Karnad, Anand B.; Glode, Michael; Crawford, E. David.

In: Oncology Reports, Vol. 16, No. 4, 01.10.2006, p. 807-810.

Research output: Contribution to journalArticle

Grossman, HB, Tangen, CM, Cordon-Cardo, C, Cote, RJ, Waldman, FM, De Vere White, RW, Karnad, AB, Glode, M & Crawford, ED 2006, 'Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group study', Oncology Reports, vol. 16, no. 4, pp. 807-810.
Grossman, H. Barton ; Tangen, Catherine M. ; Cordon-Cardo, Carlos ; Cote, Richard J ; Waldman, Frederic M. ; De Vere White, Ralph W. ; Karnad, Anand B. ; Glode, Michael ; Crawford, E. David. / Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy : A Southwest Oncology Group study. In: Oncology Reports. 2006 ; Vol. 16, No. 4. pp. 807-810.
@article{a0944e6daf3c409686164fe5806bed86,
title = "Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group study",
abstract = "In this prospective biomarker study, we evaluated the prognostic significance of Ki67, p53 and angiogenesis in patients with locally advanced bladder cancer. The patients were volunteers from a Southwest Oncology Group trial of locally advanced bladder cancer who were randomized to treatment with neoadjuvant chemotherapy plus cystectomy or cystectomy alone. Tissue specimens were obtained prior to neoadjuvant chemotherapy from 42 patients randomized to receive the combination-treatment arm and 52 randomized to cystectomy alone. The statistical power of the study was quite limited by the small sample size. The biomarkers were assayed by immunohistochemistry. Angiogenesis was determined using anti-CD34 immunostaining. Patients whose tumors had increased Ki67 expression had better progression-free survival that was marginally significant, p=0.063. The median survival in those with higher Ki67 expression was 73 months, and in those with lower expression was 38 months. However, this did not achieve statistical significance, p=0.25. There was a suggestion of worse survival among patients whose tumors exhibited altered p53 staining [hazard ratio (HR) = 1.48; p=0.15], but there was no difference in progression-free survival (HR=1.02; p=0.93). The enumeration of tumor microvessels did not provide prognostic information.",
keywords = "Angiogenesis, Bladder cancer, Ki67, p53",
author = "Grossman, {H. Barton} and Tangen, {Catherine M.} and Carlos Cordon-Cardo and Cote, {Richard J} and Waldman, {Frederic M.} and {De Vere White}, {Ralph W.} and Karnad, {Anand B.} and Michael Glode and Crawford, {E. David}",
year = "2006",
month = "10",
day = "1",
language = "English",
volume = "16",
pages = "807--810",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy

T2 - A Southwest Oncology Group study

AU - Grossman, H. Barton

AU - Tangen, Catherine M.

AU - Cordon-Cardo, Carlos

AU - Cote, Richard J

AU - Waldman, Frederic M.

AU - De Vere White, Ralph W.

AU - Karnad, Anand B.

AU - Glode, Michael

AU - Crawford, E. David

PY - 2006/10/1

Y1 - 2006/10/1

N2 - In this prospective biomarker study, we evaluated the prognostic significance of Ki67, p53 and angiogenesis in patients with locally advanced bladder cancer. The patients were volunteers from a Southwest Oncology Group trial of locally advanced bladder cancer who were randomized to treatment with neoadjuvant chemotherapy plus cystectomy or cystectomy alone. Tissue specimens were obtained prior to neoadjuvant chemotherapy from 42 patients randomized to receive the combination-treatment arm and 52 randomized to cystectomy alone. The statistical power of the study was quite limited by the small sample size. The biomarkers were assayed by immunohistochemistry. Angiogenesis was determined using anti-CD34 immunostaining. Patients whose tumors had increased Ki67 expression had better progression-free survival that was marginally significant, p=0.063. The median survival in those with higher Ki67 expression was 73 months, and in those with lower expression was 38 months. However, this did not achieve statistical significance, p=0.25. There was a suggestion of worse survival among patients whose tumors exhibited altered p53 staining [hazard ratio (HR) = 1.48; p=0.15], but there was no difference in progression-free survival (HR=1.02; p=0.93). The enumeration of tumor microvessels did not provide prognostic information.

AB - In this prospective biomarker study, we evaluated the prognostic significance of Ki67, p53 and angiogenesis in patients with locally advanced bladder cancer. The patients were volunteers from a Southwest Oncology Group trial of locally advanced bladder cancer who were randomized to treatment with neoadjuvant chemotherapy plus cystectomy or cystectomy alone. Tissue specimens were obtained prior to neoadjuvant chemotherapy from 42 patients randomized to receive the combination-treatment arm and 52 randomized to cystectomy alone. The statistical power of the study was quite limited by the small sample size. The biomarkers were assayed by immunohistochemistry. Angiogenesis was determined using anti-CD34 immunostaining. Patients whose tumors had increased Ki67 expression had better progression-free survival that was marginally significant, p=0.063. The median survival in those with higher Ki67 expression was 73 months, and in those with lower expression was 38 months. However, this did not achieve statistical significance, p=0.25. There was a suggestion of worse survival among patients whose tumors exhibited altered p53 staining [hazard ratio (HR) = 1.48; p=0.15], but there was no difference in progression-free survival (HR=1.02; p=0.93). The enumeration of tumor microvessels did not provide prognostic information.

KW - Angiogenesis

KW - Bladder cancer

KW - Ki67

KW - p53

UR - http://www.scopus.com/inward/record.url?scp=39049178363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39049178363&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 807

EP - 810

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 4

ER -